Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Neven

Showing results (111-120 of 140) with videos related to

Pageof 14
Sort By:
Journal of Geriatric Oncology|November 24, 2017
The effect of adjuvant chemotherapy on symptom burden and quality of life over time; a preliminary prospective observational study using individual data of patients aged ≥70 with early stage invasive breast cancerChantal Quinten, C Kenis, M Hamaker, et al.
Breast Cancer Research and Treatment|December 1, 2010
Prediction of lymph node involvement in breast cancer from primary tumor tissue using gene expression profiling and miRNAsA Smeets, A Daemen, I Vanden Bempt, et al.
Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology|March 11, 2010
Prospective external validation of the 'ovarian crescent sign' as a single ultrasound parameter to distinguish between benign and malignant adnexal pathologyC Van Holsbeke, V Van Belle, F P G Leone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 11, 2012
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month resultsR Coleman, R de Boer, H Eidtmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 12, 2012
Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancersO Brouckaert, A Laenen, J Vanderhaegen, et al.
ESMO Open|January 20, 2026
Exploring the treatment gap and outcome risks in patients with node-positive, high-risk, HR-positive, HER2-negative early breast cancer: analyses of real-world dataS M Tolaney, S Sammons, A Sandoval-Leon, et al.
ESMO Open|January 9, 2026
A phase IV prospective study of efficacy and safety of ribociclib and letrozole as first-line therapy in older women (≥70 years) with hormone receptor-positive HER2-negative advanced breast cancer: the RibOB studyM Van Houdt, C Kenis, L De Nys, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 2011
Stellate ganglion block for the management of hot flashes and sleep disturbances in breast cancer survivors: an uncontrolled experimental study with 24 weeks of follow-upK Haest, A Kumar, B Van Calster, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 2016
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)G Jerusalem, G Mariani, E M Ciruelos, et al.
Journal of Cancer Research and Clinical Oncology|January 20, 2021
Features of durable response and treatment efficacy for capecitabine monotherapy in advanced breast cancer: real-world evidence from a large single-centre cohortS Thijssen, H Wildiers, K Punie, et al.
Pageof 14

Showing results (111-120 of 140) with videos related to

Sort By:
Pageof 14
Journal of Geriatric Oncology|November 24, 2017
The effect of adjuvant chemotherapy on symptom burden and quality of life over time; a preliminary prospective observational study using individual data of patients aged ≥70 with early stage invasive breast cancerChantal Quinten, C Kenis, M Hamaker, et al.
Breast Cancer Research and Treatment|December 1, 2010
Prediction of lymph node involvement in breast cancer from primary tumor tissue using gene expression profiling and miRNAsA Smeets, A Daemen, I Vanden Bempt, et al.
Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology|March 11, 2010
Prospective external validation of the 'ovarian crescent sign' as a single ultrasound parameter to distinguish between benign and malignant adnexal pathologyC Van Holsbeke, V Van Belle, F P G Leone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 11, 2012
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month resultsR Coleman, R de Boer, H Eidtmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 12, 2012
Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancersO Brouckaert, A Laenen, J Vanderhaegen, et al.
ESMO Open|January 20, 2026
Exploring the treatment gap and outcome risks in patients with node-positive, high-risk, HR-positive, HER2-negative early breast cancer: analyses of real-world dataS M Tolaney, S Sammons, A Sandoval-Leon, et al.
ESMO Open|January 9, 2026
A phase IV prospective study of efficacy and safety of ribociclib and letrozole as first-line therapy in older women (≥70 years) with hormone receptor-positive HER2-negative advanced breast cancer: the RibOB studyM Van Houdt, C Kenis, L De Nys, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 2011
Stellate ganglion block for the management of hot flashes and sleep disturbances in breast cancer survivors: an uncontrolled experimental study with 24 weeks of follow-upK Haest, A Kumar, B Van Calster, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 2016
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)G Jerusalem, G Mariani, E M Ciruelos, et al.
Journal of Cancer Research and Clinical Oncology|January 20, 2021
Features of durable response and treatment efficacy for capecitabine monotherapy in advanced breast cancer: real-world evidence from a large single-centre cohortS Thijssen, H Wildiers, K Punie, et al.
Pageof 14